Due to technical maintenance the webshop is closed until January 3, 4. We wish you a successful 2024!
LEIDEN April 23, 2019 - BIOKÉ, a business unit of Cell Signaling Technology Europe (CST Europe) announced that they have signed an agreement with GE Healthcare allowing BIOKÉ to distribute the GE's Amersham Typhoon Gel and Blot imaging systems in the BeNeLux countries (Netherlands, Belgium, Luxembourg), effective immediately.
"We are excited to work together with GE Healthcare. The Typhoon biomolecular imagers offer precise quantitation of fluorescent, colour-stained and radio-labelled biomolecules like proteins and nucleic acids. The versatility and sensitivity are unique in the market," said Robert Hovingh, Sales Manager BIOKÉ, "The addition of these imaging systems to our BIOKÉ product portfolio will strengthen our ability to provide a complete solution to our customers that are performing research in the protein & cellular analysis field."
Founded in 2004, BIOKÉ is an experienced and knowledgeable company that provides innovative products with the highest quality in the life science industry throughout Europe. BIOKÉ delivers unique and high-performance applications and workflows for genomics, protein analysis and cell biology. In July 2009 Cell Signaling Technology, Inc. (CST) - the market leader in the development of high quality antibody products and technologies - acquired BIOKÉ BV and BIOKÉ became a business unit of Cell Signaling Technology Europe (CST EU). CST EU and BIOKÉ hold offices in Leiden, the Netherlands. For additional information please visit our website at www.bioke.com.